CellaVision AB (publ) (CEVI.ST) Stock Analysis & Winston Score

CellaVision makes digital camera systems that hospitals and labs use to analyze blood cells. Instead of a person staring through a microscope for hours, CellaVision's machines take high-resolution images of blood samples and use software to automatically identify and count different types of cells. The company sells to hospital laboratories, blood banks, and diagnostic clinics around the world, and it is the global market leader in digital cell morphology. CellaVision earns money by selling its hardware analyzers and then charging ongoing fees for software licenses, reagents, and service contracts — a model that creates recurring revenue after the initial sale. The company is headquartered in Sweden and operates globally, with strong presence in North America, Europe, and Asia. Its moat comes from being deeply embedded in lab workflows, with switching costs that make it hard for customers to change systems once trained. The key growth driver is the ongoing shift from manual microscope analysis to digital automation, which is still early in many parts of the world.